【原美源伯根】Cencora (COR) 2018年年度报告「NYSE」.pdf

1、2018 Summary Annual ReportIn This Report03About AmerisourceBergen04CEO Statement:To Our Stockholders082018 Overview12Management Committee13Board of Directors14GAAP/Non-GAAP Financial Measures15Corporate InformationAbout AmerisourceBergen AmerisourceBergen is one of the largest global pharmaceutical

2、sourcing and distribution services companies,helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consult

3、ing services,AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel in human and animal health.With over$160 billion in annual revenue,AmerisourceBergen is headquartered in Valley Forge,PA,and employs approximately 21,000 people around the world.Ameriso

4、urceBergen is ranked#12 on the Fortune 500 list.We distribute a comprehensive offering of brand name and generic pharmaceuticals including specialty pharmaceutical products,over-the-counter healthcare products,home healthcare supplies and equipment,outsourced compounded sterile preparations,and rela

5、ted services to a wide variety of healthcare providers located in the United States and select global markets.Our customers include chain retail and independent pharmacies,mail order pharmacies,acute care hospitals and health systems,physician practices,medical and dialysis clinics,long-term care an

6、d other alternate site pharmacies,veterinarians,and others.Additionally,we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related high-value services,including reimbursement and pharmaceutical consulting services,niche premium logistics services,inventory managem